TherapeuticsMD Statistics
Total Valuation
TherapeuticsMD has a market cap or net worth of $11.30 million. The enterprise value is $11.32 million.
Important Dates
The next estimated earnings date is Friday, May 9, 2025, after market close.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TherapeuticsMD has 11.53 million shares outstanding. The number of shares has increased by 10.45% in one year.
| Current Share Class | 11.53M |
| Shares Outstanding | 11.53M |
| Shares Change (YoY) | +10.45% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | 14.76% |
| Float | 9.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.06 |
| Forward PS | n/a |
| PB Ratio | 0.39 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | 14.81 |
| P/OCF Ratio | 14.81 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 15.47 |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 0.20.
| Current Ratio | 2.37 |
| Quick Ratio | 1.67 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | 7.57 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -8.16% and return on invested capital (ROIC) is -6.22%.
| Return on Equity (ROE) | -8.16% |
| Return on Assets (ROA) | -5.31% |
| Return on Invested Capital (ROIC) | -6.22% |
| Return on Capital Employed (ROCE) | -10.38% |
| Revenue Per Employee | $1.76M |
| Profits Per Employee | -$2.18M |
| Employee Count | 1 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -31,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.21% in the last 52 weeks. The beta is 1.17, so TherapeuticsMD's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | -57.21% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 1.41 |
| Relative Strength Index (RSI) | 55.23 |
| Average Volume (20 Days) | 56,232 |
Short Selling Information
The latest short interest is 170,162, so 1.48% of the outstanding shares have been sold short.
| Short Interest | 170,162 |
| Short Previous Month | 210,509 |
| Short % of Shares Out | 1.48% |
| Short % of Float | 1.80% |
| Short Ratio (days to cover) | 0.21 |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of $1.76 million and -$2.18 million in losses. Loss per share was -$0.19.
| Revenue | 1.76M |
| Gross Profit | 1.76M |
| Operating Income | -3.49M |
| Pretax Income | -6.13M |
| Net Income | -2.18M |
| EBITDA | -2.98M |
| EBIT | -3.49M |
| Loss Per Share | -$0.19 |
Full Income StatementBalance Sheet
The company has $5.06 million in cash and $5.54 million in debt, giving a net cash position of -$483,000 or -$0.04 per share.
| Cash & Cash Equivalents | 5.06M |
| Total Debt | 5.54M |
| Net Cash | -483,000 |
| Net Cash Per Share | -$0.04 |
| Equity (Book Value) | 27.37M |
| Book Value Per Share | 2.37 |
| Working Capital | 7.09M |
Full Balance SheetCash Flow
| Operating Cash Flow | 732,000 |
| Capital Expenditures | n/a |
| Free Cash Flow | 732,000 |
| FCF Per Share | $0.06 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -198.30% and -123.85%.
| Gross Margin | 100.00% |
| Operating Margin | -198.30% |
| Pretax Margin | -133.05% |
| Profit Margin | -123.85% |
| EBITDA Margin | -169.39% |
| EBIT Margin | -198.30% |
| FCF Margin | 41.57% |